Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00892567 · ClinicalTrials.gov registry record · Phase 1
Evaluating the T Cell Response to a Peptide-based Vaccine in Patients With Breast Cancer
A Phase 1 study of Breast Neoplasms, sponsored by Craig L Slingluff, Jr.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT00892567: Completed Phase 1 study of Breast Neoplasms, sponsored by Craig L Slingluff, Jr.
NCT00892567 is a Phase 1 study of Breast Neoplasms that has completed, run by Craig L Slingluff, Jr. The registered enrollment target is 9 participants, below the 569-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00892567, a Phase 1 study of Breast Neoplasms, has completed, sponsored by Craig L Slingluff, Jr.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate T cell responses against a peptide-based vaccine in patients with breast cancer and to determine whether peptide-specific T cells can be found at the site of breast tumors following vaccination.
Conditions Studied
Interventions
- BIOLOGICAL 9 Peptides from Her-2/neu, CEA, & CTA
Study Locations (1)
Virginia
- University of Virginia Health System - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2009-05 |
| Est. Completion | 2012-02 |
| Phase | Phase 1 |
What the finished NCT00892567 record still lists
NCT00892567 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 569-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Breast Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which 9 Peptides from Her-2/neu, CEA, & CTA is the first listed.
NCT00892567 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT00892567 about?
NCT00892567 is a clinical study titled "Evaluating the T Cell Response to a Peptide-based Vaccine in Patients With Breast Cancer". The purpose of this study is to evaluate T cell responses against a peptide-based vaccine in patients with breast cancer and to determine whether peptide-specific T cells can be found at the site of breast tumors following vaccination.
What is the current status of trial NCT00892567?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2009-05. Estimated completion is 2012-02.
What conditions does trial NCT00892567 study?
This clinical trial studies the following conditions: Breast Neoplasms.
What interventions are being tested in trial NCT00892567?
The interventions under investigation include: 9 Peptides from Her-2/neu, CEA, & CTA (BIOLOGICAL).
Who is sponsoring clinical trial NCT00892567?
This trial is sponsored by Craig L Slingluff, Jr, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00892567 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00892567's enrollment target sits among peer trials
9 98th of 97 the lowest of 97 other Breast Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
RECRUITING · Phase 1
-
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
RECRUITING · Phase 1
-
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
RECRUITING · Phase 1
-
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
RECRUITING · Phase 1
-
A Study of DM001 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia